Vericel (NASDAQ:VCEL) Hits New 52-Week Low at $30.11

Vericel Co. (NASDAQ:VCELGet Rating) hit a new 52-week low during trading on Thursday . The company traded as low as $30.11 and last traded at $30.25, with a volume of 10509 shares trading hands. The stock had previously closed at $31.99.

A number of research analysts recently commented on VCEL shares. StockNews.com started coverage on Vericel in a research note on Thursday, March 31st. They issued a “sell” rating for the company. TheStreet lowered Vericel from a “c-” rating to a “d+” rating in a research note on Thursday, March 31st. Zacks Investment Research lowered Vericel from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 12th. Finally, SVB Leerink increased their price objective on Vericel from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Friday, February 25th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Vericel currently has a consensus rating of “Hold” and an average price target of $54.00.

The firm has a 50 day simple moving average of $36.43 and a 200-day simple moving average of $38.78. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -167.65 and a beta of 1.87.

Vericel (NASDAQ:VCELGet Rating) last released its quarterly earnings data on Thursday, February 24th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.08). Vericel had a negative return on equity of 4.83% and a negative net margin of 4.78%. The company had revenue of $47.60 million for the quarter, compared to analyst estimates of $48.09 million. During the same quarter in the prior year, the company earned $0.25 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts anticipate that Vericel Co. will post -0.18 earnings per share for the current year.

Large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC increased its stake in shares of Vericel by 114.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,565 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 2,970 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Vericel by 5.2% in the fourth quarter. New York State Common Retirement Fund now owns 718,796 shares of the biotechnology company’s stock valued at $28,249,000 after buying an additional 35,755 shares in the last quarter. Fisher Asset Management LLC increased its stake in shares of Vericel by 18.9% in the fourth quarter. Fisher Asset Management LLC now owns 1,236,675 shares of the biotechnology company’s stock valued at $48,601,000 after buying an additional 196,635 shares in the last quarter. BNP Paribas Asset Management Holding S.A. increased its stake in shares of Vericel by 38.8% in the third quarter. BNP Paribas Asset Management Holding S.A. now owns 446,492 shares of the biotechnology company’s stock valued at $21,789,000 after buying an additional 124,912 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of Vericel by 9.6% in the third quarter. State of New Jersey Common Pension Fund D now owns 52,911 shares of the biotechnology company’s stock valued at $2,582,000 after buying an additional 4,614 shares in the last quarter.

About Vericel (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns.

Featured Articles

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.